In vivo base editing technologies for liver diseases (Europe/UK)

Background
What we're looking for
What we can offer you
Who we are
Q&A

Have questions about this request?

Get them answered by the team at Takeda.

Background

Under our purpose “Better Health for People, Brighter Future for the World”, Takeda actively engages in diverse open innovation initiatives to advance patient-focused scientific breakthroughs.

We are currently seeking platform technologies to address unmet medical needs in the Gastrointestinal (GI) therapeutic area. We are specifically interested in partnering with academia and startups across Europe and the UK.

What we're looking for

We are seeking in vivo base editing technologies for disease-causing DNA mutations. Novel editing enzymes with potential to be developed as mRNA/LNP targeting hepatocytes are particularly desired.

Our must-have requirements are:

The researcher belongs to an academic institution or startup in Europe or the UK (If you are interested in participating but are not based in this region, please record your interest in this form.)
The proposed project can be completed at a cost that is economically feasible within a 1 year timeline
The proposed project is based on highly differentiated approaches/concepts that comes with an opportunity to develop IP on novel therapeutics in the GI therapeutic area

What we can offer you

Eligible partnership models:

Sponsored Research

Funding is available up to €50,000 over 1 year for construction and validation of novel platform technologies toward pharmaceutical application in GI disease.

Expertise

Takeda may provide chemical, biologic, imaging, or clinical expertise as needed.

Who we are

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

Learn more

Reviewers

Yoji Ueda

Associate Director

John Ballew

Takeda Academic Innovation

Suzanne Collins

Sr. Director

Q&A with Takeda

The Q&A is now closed.

Sort by:

We have RNA editing technology but are based in Japan. Could you also consider a Japanese start-up?

Atsushi Shimada, Business Development, The University of Tokyo Edge Capital Partners

July 20, 2023

Thank you for your interest in this RFP. However, since our primary focus is on EU/UK at this time, we are sorry but an application from Japan is ineligible to apply.

Yoji Ueda, Associate Director, Takeda

July 25, 2023

Is this response helpful?

I am a PI at Clemson University, located in South Carolina, USA doing relevant research in this area. Are researchers at American universities eligible to apply? If not, are there any alternative partnership opportunities you would be open to?

Renee Cottle, Principal Investigator, Clemson University

July 6, 2023

We appreciate your interest in this RFP. However, since our primary focus is on EU/UK at this time, we are sorry but you are ineligible to apply. We will consider including other regions in the future RFPs.

Yoji Ueda, Associate Director, Takeda

July 11, 2023

Is this response helpful?

We are active in the field of precise gene-editing in the liver; would a project focusing on prime editing rather than base editing also fall under the scope of this call? Prime editing is more versatile and may be beneficial for many more different patients.

Sabine Fuchs, Principal Investigator, Utrecht University

August 10, 2023

Thanks for reaching out! The short answer would be yes, we would be very happy to hear about any innovative approach in this space. Please be aware that our interest lies in in vivo editing, therefore it is highly desirable that the proposed technology is expected to be compatible with envisioned delivery vehicle (e.g. LNP).

Ken Fujimura, Director, Takeda

August 11, 2023

Is this response helpful?

We use genome targeting in vivo (mice) in hepatocytes with AAVs and mRNA-LNPs in ornithine transcarbamylase deficiency, which is not exactly a GI disease but the genetic defect is in the liver. Does it fit in this call?

Andres Muro, Principal Investigator, International Centre for Genetic Engineering and Biotechnology

August 17, 2023

Thanks for the inquiry! The answer would be yes, if your technology or envisioned research plan has broader implications that extend beyond OTC deficiency. If the scope of your work is strictly limited to this particular disease, it may not be a good fit. Hope this helps.

Ken Fujimura, Director, Takeda

August 17, 2023

Is this response helpful?

Would you be interested in our platform technology that is used to assess the safe and efficacious design of guide RNA’s for both nuclease-dependent (eg Cas9) and nuclease-independent (eg base or prime) editing systems?

Simon Reed, CSO, Broken String Biosciences

August 28, 2023

Thank you for your interest in our RFP. However, your technology seems out of the scope for this particular RFP.

Yoji Ueda, Associate Director, Takeda

August 30, 2023

Is this response helpful?

View the details of this request and connect directly with corporate R&D teams at Fortune 500 companies.

Share partnering request

Complete

Refine recommendations

Is this request relevant to you?

Eligible partners